The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The effect of dose reduction of talquetamab in patients with R/R MM: results from MonumenTAL-1
Ajai Chari, MD, UCSF, San Francisco, CA, discusses the outcomes of talquetamab dose modification in a group of patients with relapsed/refractory (R/R) multiple myeloma (MM) enrolled in the MonumenTAL-1 trial (NCT04634552). Talquetamab elicits some on-target off-tumor effects in many patients, with unique side effects such as dysgeusia and nail- or skin-related adverse events (AEs). Reducing the dosing intensity was not found to compromise the efficacy of the treatment in these patients, and some improvement in treatment-related AEs was observed. Additionally, a unique finding was made, as the occurrence of AEs in the first three months of treatment was associated with a 20% higher likelihood of responding to the drug. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Glaxo Smith Kline, AbbVie, Seattle Genetics, Amgen, BMS, Janssen, Sanofi, Shattuck Labs, Genentech, Karyopharm, Secura Bio
Consultancy: Millenium/Takeda, Amgen, BMS, Janssen, Antengene, Secura Bio
Research Funding: Millenium/Takeda, Seattle Genetics, Amgen, BMS, Janssen
